U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Benign prostatic hyperplasia(BPH)

MedGen UID:
312369
•Concept ID:
C1704272
•
Pathologic Function
Synonym: BPH
SNOMED CT: Nodular hyperplasia of prostate gland (266569009); BPH - benign prostatic hyperplasia (266569009); Benign prostatic hyperplasia (266569009); Benign enlargement of prostate (266569009); Benign prostatic hypertrophy (266569009); BEP - Benign enlargement of prostate (266569009)
 
HPO: HP:0008711
Monarch Initiative: MONDO:0010811
OMIM®: 600082

Definition

Benign prostatic hyperplasia (BPH) refers to the nonmalignant growth of the prostate gland, and is histologically defined as hyperplasia of the prostate gland. BPH is an age-related phenomenon in men beginning at about age 40 years. BPH may result in prostatic enlargement and clinical symptoms most commonly affecting the lower urinary tract. These symptoms may be obstructive, including hesitancy, weak flow, and urinary retention, or irritative, including increased frequency and urgency. However, not all men with histologic BPH will develop prostatic enlargement or urinary symptoms (review by Roehrborn, 2005). [from OMIM]

Clinical features

From HPO
Benign prostatic hyperplasia
MedGen UID:
312369
•Concept ID:
C1704272
•
Pathologic Function
Benign prostatic hyperplasia (BPH) refers to the nonmalignant growth of the prostate gland, and is histologically defined as hyperplasia of the prostate gland. BPH is an age-related phenomenon in men beginning at about age 40 years. BPH may result in prostatic enlargement and clinical symptoms most commonly affecting the lower urinary tract. These symptoms may be obstructive, including hesitancy, weak flow, and urinary retention, or irritative, including increased frequency and urgency. However, not all men with histologic BPH will develop prostatic enlargement or urinary symptoms (review by Roehrborn, 2005).
See: Feature record | Search on this feature

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVBenign prostatic hyperplasia

Conditions with this feature

Benign prostatic hyperplasia
MedGen UID:
312369
•Concept ID:
C1704272
•
Pathologic Function
Benign prostatic hyperplasia (BPH) refers to the nonmalignant growth of the prostate gland, and is histologically defined as hyperplasia of the prostate gland. BPH is an age-related phenomenon in men beginning at about age 40 years. BPH may result in prostatic enlargement and clinical symptoms most commonly affecting the lower urinary tract. These symptoms may be obstructive, including hesitancy, weak flow, and urinary retention, or irritative, including increased frequency and urgency. However, not all men with histologic BPH will develop prostatic enlargement or urinary symptoms (review by Roehrborn, 2005).
See: Condition Record
Benign prostatic hyperplasia

Professional guidelines

PubMed

Medical Treatment of Benign Prostatic Hyperplasia.
Plochocki A, King B
Urol Clin North Am 2022 May;49(2):231-238. Epub 2022 Mar 22 doi: 10.1016/j.ucl.2021.12.003. PMID: 35428429
Treatment of Benign Prostatic Hyperplasia by Natural Drugs.
Csikós E, Horváth A, Ács K, Papp N, Balázs VL, Dolenc MS, Kenda M, Kočevar Glavač N, Nagy M, Protti M, Mercolini L, Horváth G, Farkas Á, On Behalf Of The Oemonom
Molecules 2021 Nov 25;26(23) doi: 10.3390/molecules26237141. PMID: 34885733Free PMC Article
Current Treatment for Benign Prostatic Hyperplasia.
Miernik A, Gratzke C
Dtsch Arztebl Int 2020 Dec 4;117(49):843-854. doi: 10.3238/arztebl.2020.0843. PMID: 33593479Free PMC Article

Recent clinical studies

Etiology

Surgical Complications in the Management of Benign Prostatic Hyperplasia Treatment.
Ottaiano N, Shelton T, Sanekommu G, Benson CR
Curr Urol Rep 2022 May;23(5):83-92. Epub 2022 Mar 9 doi: 10.1007/s11934-022-01091-z. PMID: 35262855
The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction.
Bearelly P, Avellino GJ
Fertil Steril 2021 Sep;116(3):611-617. doi: 10.1016/j.fertnstert.2021.07.1199. PMID: 34462095
Quality of life and erectile dysfunction in patients with benign prostatic hyperplasia.
Montiel-Jarquín ÁJ, Gutiérrez-Quiroz CT, Pérez-Vázquez AL, Ortiz-Agustín JJ, García-Galicia A, Loría-Castellanos J
Cir Cir 2021;89(2):218-222. doi: 10.24875/CIRU.20000071. PMID: 33784271
Current Treatment for Benign Prostatic Hyperplasia.
Miernik A, Gratzke C
Dtsch Arztebl Int 2020 Dec 4;117(49):843-854. doi: 10.3238/arztebl.2020.0843. PMID: 33593479Free PMC Article
Benign prostatic hyperplasia and lower urinary tract symptoms. A review of current evidence.
Carrero-López VM, Cózar-Olmo JM, Miñana-López B
Actas Urol Esp 2016 Jun;40(5):288-94. Epub 2016 Jan 25 doi: 10.1016/j.acuro.2015.12.008. PMID: 26823069

Diagnosis

Current Treatment for Benign Prostatic Hyperplasia.
Miernik A, Gratzke C
Dtsch Arztebl Int 2020 Dec 4;117(49):843-854. doi: 10.3238/arztebl.2020.0843. PMID: 33593479Free PMC Article
An overview of hydronephrosis in adults.
Patel K, Batura D
Br J Hosp Med (Lond) 2020 Jan 2;81(1):1-8. Epub 2020 Jan 28 doi: 10.12968/hmed.2019.0274. PMID: 32003628
Urinary Retention.
Billet M, Windsor TA
Emerg Med Clin North Am 2019 Nov;37(4):649-660. Epub 2019 Aug 16 doi: 10.1016/j.emc.2019.07.005. PMID: 31563200
Benign Prostatic Hyperplasia.
Langan RC
Prim Care 2019 Jun;46(2):223-232. Epub 2019 Apr 1 doi: 10.1016/j.pop.2019.02.003. PMID: 31030823
What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
Foo KT
World J Urol 2019 Jul;37(7):1293-1296. Epub 2019 Feb 25 doi: 10.1007/s00345-019-02691-0. PMID: 30805683Free PMC Article

Therapy

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED.
Sebastianelli A, Spatafora P, Morselli S, Vignozzi L, Serni S, McVary KT, Kaplan S, Gravas S, Chapple C, Gacci M
Curr Urol Rep 2020 Oct 27;21(12):56. doi: 10.1007/s11934-020-01009-7. PMID: 33108544Free PMC Article
Post-finasteride syndrome: a surmountable challenge for clinicians.
Traish AM
Fertil Steril 2020 Jan;113(1):21-50. doi: 10.1016/j.fertnstert.2019.11.030. PMID: 32033719
Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.
Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW
Sex Med Rev 2019 Jan;7(1):84-94. Epub 2018 Nov 30 doi: 10.1016/j.sxmr.2018.09.006. PMID: 30503797Free PMC Article
Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications.
Sun F, Sun X, Shi Q, Zhai Y
Medicine (Baltimore) 2018 Dec;97(51):e13360. doi: 10.1097/MD.0000000000013360. PMID: 30572440Free PMC Article
Serenoa repens for benign prostatic hyperplasia.
Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ
Cochrane Database Syst Rev 2012 Dec 12;12(12):CD001423. doi: 10.1002/14651858.CD001423.pub3. PMID: 23235581Free PMC Article

Prognosis

Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists.
Sasane R, Bartels A, Field M, Sierra MI, Duvvuri S, Gray DL, Pin SS, Renger JJ, Stone DJ
J Clin Invest 2021 Jun 1;131(11) doi: 10.1172/JCI145112. PMID: 33822767Free PMC Article
AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer.
Zhou J, He Z, Ma S, Liu R
Cancer Med 2020 Aug;9(15):5672-5677. Epub 2020 Jun 20 doi: 10.1002/cam4.3086. PMID: 32562455Free PMC Article
Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y, Grady JJ, Albertsen PC, Helen Wu Z
Pharmacoepidemiol Drug Saf 2018 Mar;27(3):340-348. Epub 2018 Jan 9 doi: 10.1002/pds.4361. PMID: 29316005
The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates.
Egan KB
Urol Clin North Am 2016 Aug;43(3):289-97. doi: 10.1016/j.ucl.2016.04.001. PMID: 27476122
Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention.
Rassweiler J, Teber D, Kuntz R, Hofmann R
Eur Urol 2006 Nov;50(5):969-79; discussion 980. Epub 2006 Jan 30 doi: 10.1016/j.eururo.2005.12.042. PMID: 16469429

Clinical prediction guides

An Indirect Comparison of Newer Minimally Invasive Treatments for Benign Prostatic Hyperplasia: A Network Meta-Analysis Model.
Tanneru K, Jazayeri SB, Alam MU, Kumar J, Bazargani S, Kuntz G, Palayapalayam Ganapathi H, Bandyk M, Marino R, Koochekpour S, Gautam S, Balaji KC, Costa J
J Endourol 2021 Apr;35(4):409-416. Epub 2021 Jan 25 doi: 10.1089/end.2020.0739. PMID: 32962442
Benign Prostatic Hyperplasia: Clinical Manifestations, Imaging, and Patient Selection for Prostate Artery Embolization.
Powell T, Kellner D, Ayyagari R
Tech Vasc Interv Radiol 2020 Sep;23(3):100688. Epub 2020 Oct 6 doi: 10.1016/j.tvir.2020.100688. PMID: 33308530
Benign prostatic hyperplasia: clinical manifestations and evaluation.
Santos Dias J
Tech Vasc Interv Radiol 2012 Dec;15(4):265-9. doi: 10.1053/j.tvir.2012.09.007. PMID: 23244722
Benign prostatic hyperplasia and lower urinary tract symptoms: research priorities.
De Nunzio C, Ahyai S, Autorino R, Bachmann A, Bialek W, Briganti A, Reich O, Sosnowski R, Thiruchelvam N, Novara G; European Association of Urology Young Academic Urologists BPH Group
Eur Urol 2011 Dec;60(6):1205-6. Epub 2011 Sep 7 doi: 10.1016/j.eururo.2011.08.055. PMID: 21930341
The Abrams-Griffiths nomogram.
Lim CS, Abrams P
World J Urol 1995;13(1):34-9. doi: 10.1007/BF00182664. PMID: 7539679

Recent systematic reviews

Minimally Invasive Treatments for Benign Prostatic Hyperplasia: Systematic Review and Network Meta-Analysis.
Sajan A, Mehta T, Desai P, Isaacson A, Bagla S
J Vasc Interv Radiol 2022 Apr;33(4):359-367.e8. Epub 2021 Dec 27 doi: 10.1016/j.jvir.2021.12.029. PMID: 34968671
Systematic Review and Meta-analysis Comparing Prostatic Artery Embolization to Gold-Standard Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia.
Knight GM, Talwar A, Salem R, Mouli S
Cardiovasc Intervent Radiol 2021 Feb;44(2):183-193. Epub 2020 Oct 19 doi: 10.1007/s00270-020-02657-5. PMID: 33078236
Benign prostate hyperplasia and nutrition.
Das K, Buchholz N
Clin Nutr ESPEN 2019 Oct;33:5-11. Epub 2019 Aug 12 doi: 10.1016/j.clnesp.2019.07.015. PMID: 31451276
Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications.
Sun F, Sun X, Shi Q, Zhai Y
Medicine (Baltimore) 2018 Dec;97(51):e13360. doi: 10.1097/MD.0000000000013360. PMID: 30572440Free PMC Article
Benign prostatic hyperplasia: epidemiology, economics and evaluation.
Vuichoud C, Loughlin KR
Can J Urol 2015 Oct;22 Suppl 1:1-6. PMID: 26497338

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • MeSH
      Related Medical Subject Headings
    • OMIM
      Related records in OMIM
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed
    • PubMed (OMIM)
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...